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The zinc finger protein Klf7 and POU homeodomain protein Brn3a are each required for efficient transcription of TrkA in primary sensory
neurons. In this study, we examined whether these transcription factors act in concert to regulate TrkA expression. In vitro, Brn3a and Klf7 can
synergistically activate the TrkA enhancer. In vivo, precursor cells that are destined to become TrkA(+) neurons are born. However, both Brn3a and
Klf7 are dispensable for the initiation of TrkA expression. At E12.5, while TrkA expression is unaffected in Brn3a−/− trigeminal ganglia and only
slightly decreased inKlf7−/− trigeminal ganglia, it is severely reduced in the doublemutant Brn3a−/−;Klf7−/− trigeminal ganglia. At birth, all Trk(+)
neurons are lost in Brn3a−/−;Klf7−/− trigeminal ganglia. We further demonstrate that the TrkA enhancer is inactive in Brn3a−/−;Klf7−/− trigeminal
ganglia. Thus, cooperation between these two transcription factors is required for endogenous TrkA gene expression and the survival of nociceptive
sensory neurons.
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In the vertebrate nervous system, Trk family receptor
tyrosine kinases mediate the function of the nerve growth
factor (NGF) family of neurotrophins (Huang and Reichardt,
2001, 2003; Parada et al., 1992). TrkA is the receptor for NGF,
TrkB is the receptor for brain-derived neurotrophic factor
(BDNF) and neurotrophin 4 (NT4), and TrkC is the receptor for
NT3. As classical receptor tyrosine kinases, upon neurotrophin
binding, Trk receptors initiate several well-defined signaling
pathways, including the ras-MAP kinase pathway, the PI3
kinase-Akt pathway, and the PLCγ-PKCδ pathway, which in
turn control cell fate specification, neuronal survival, prolifer-
ation, differentiation, axonal growth and target innervation, and
long-term potentiation (LTP) (Bibel and Barde, 2000; Huang
and Reichardt, 2001, 2003). One central aspect of neurotrophin⁎ Corresponding author. Fax: +1 214 648 1960.
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doi:10.1016/j.ydbio.2006.08.062and Trk receptor biology is that while neurotrophins are
secreted molecules and largely derived from the target tissues,
Trk receptors are differentially expressed, which determines the
cell-type-specific function of different neurotrophins and Trk
receptors. For example, within neural crest-derived sensory
neurons, TrkA is expressed in the small diameter nociceptive
sensory neurons and these neurons disappear in NGF−/− and
TrkA−/− mice (Crowley et al., 1994; Liebl et al., 1997; Martin-
Zanca et al., 1990; Smeyne et al., 1994). TrkB is expressed in
the medium sized mechanoreceptive sensory neurons and a
subset of these neurons disappears in TrkB−/− and BDNF−/−
mice (Jones et al., 1994; Klein et al., 1989, 1990, 1991, 1993;
Liebl et al., 1997). TrkC is expressed in the large diameter
proprioceptive neurons and these neurons disappear in TrkC−/−
and NT3−/−mice (Farinas et al., 1994, 1996; Klein et al., 1994;
Liebl et al., 1997; Tessarollo et al., 1993, 1994, 1997; Wilkinson
et al., 1996). A small population of dorsal root ganglion (DRG)
and trigeminal ganglion neurons do not express Trk
receptors but instead express Ret, the receptor for glial
cell line derived neurotrophic factor (GDNF) (Bennett et al.,
1998; Huang et al., 1999; Molliver et al., 1997). The ectopic
expression of TrkC from the endogenous TrkA locus
resulted in conversion of a fraction of nociceptive neurons
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importance of precise transcriptional control of Trk receptors
(Moqrich et al., 2004).
We previously identified a TrkA minimal enhancer that in
transgenic mice drives the expression of a β-galactosidase
reporter gene specifically in the TrkA(+) sensory neurons (Ma
et al., 2000). This 457-bp DNA fragment contains nine highly
conserved cis elements that are important for complete
enhancer function in vivo (Ma et al., 2000). This implies that
the in vivo expression of TrkA is controlled by the cooperation
of multiple transcription factors. By using an expression
cloning approach, we identified the zinc finger transcription
factor Klf7 as able to bind one of these cis elements (Lei et al.,
2001). Klf7 can activate the TrkA minimal enhancer in a
sequence-dependent manner and Klf7−/− mice have reduced
TrkA expression and compromised survival of about 50% of
nociceptive sensory neurons (Lei et al., 2005). The down-
regulation of TrkA expression is a direct effect of Klf7 gene
ablation, rather than a secondary effect of cell death. The
expression of TrkB, TrkC, and Ret is normal in Klf7−/− DRG.
As a result, Klf7−/− mice have a specific defect in nociception,
the sensation of pain and noxious stimuli, while they have
normal mechanoreception, the sensation of innocuous mechan-
ical stimuli, and proprioception, the sensation of body position
and limb placement (Lei et al., 2005).
Brn3a is a class IV POU homeodomain transcription
factor (Gerrero et al., 1993; He et al., 1989). It is highly
expressed in primary sensory neurons in the peripheral
nervous system (PNS) and in selected brain stem nuclei in
the central nervous system (CNS) (Artinger et al., 1998;
Fedtsova and Turner, 1995; Ninkina et al., 1993; Xiang et al.,
1995). The expression of Trk receptors is greatly reduced in
Brn3a−/− mice (Eng et al., 2001; Huang et al., 1999;
McEvilly et al., 1996; Xiang et al., 1996). It was previously
reported that while initial expression of TrkA from E10.5 to
E13.5 is normal in Brn3a−/− trigeminal ganglia, expression
gradually disappears afterwards (Huang et al., 1999). The
same study reported that in Brn3a null embryos, initial
expression of TrkB in sensory neurons is slightly increased
but disappears by P0. TrkC expression is completely ablated
from as early as E10.5. However, our studies of Brn3a
mutants that included in situ hybridization, immunohisto-
chemistry, and TrkA enhancer analysis, indicated that the
expression of TrkA is reduced but not ablated in Brn3a−/−
trigeminal ganglia (Ma et al., 2003). This down-regulation of
TrkA expression is a direct effect of Brn3a gene ablation,
rather than a secondary effect of cell death and is mediated
by two Brn3a binding sites within the TrkA minimal
enhancer that are important for the enhancer function,
suggesting that Brn3a may directly regulate TrkA expression
(Ma et al., 2003).
In the current study, we examine the relative function of
Brn3a and Klf7 in regulating TrkA transcription. Our data
indicate that Klf7 and Brn3a synergistically activate the
TrkA minimal enhancer in vitro and the deletion of both
genes leads to a complete loss of TrkA gene expression in
sensory neurons in vivo.Material and methods
Breeding and genotyping of Klf7 and Brn3a mutant mice
Mice were housed and maintained according to the UTSW IACUC
guidelines. Genotyping of Klf7 and Brn3a mutant mice was done as
previously described (Lei et al., 2005; Ma et al., 2003). Klf7+/− mice were
mated with Brn3a+/− mice to generate Brn3a+/−;Klf7+/− double heterozy-
gous mice, which were then used to generate the single and double knockouts.
The Brn3a+/−;Klf7+/− embryos used as controls are indistinguishable from
wild-type littermates with respect to sensory neuron survival and marker
expression.
Dual luciferase reporter assays
Transient transfection and dual luciferase reporter assays using PC12 cells were
done as previously described (Lei et al., 2005). The reporter construct contains the
wild-type TrkA minimal enhancer upstream of the SV40 minimal promoter and the
firefly luciferase gene. Transfection was done in triplicates using 6-well plates and
Fugene 6 reagent (Roche). For each transfection, the reporter construct (1 μg) was
added together with myc-Brn3a, myc-Klf7, or both, in the presence of 30 ng
pCMV-Renila vector that contains the Renila luciferase gene under the control of
the CMV promoter/enhancer (Promega). The total amount of expression vectors
was adjusted to 4 μg per well using the myc-tagged cloning vector CS2+MT. 48 h
after transfection, cell lysates were collected and both firefly luciferase and Renila
luciferase activities were measured using a POLARstar OPTIMA plate reader
(BMG Labtech). The activity of the firefly luciferase was divided by that of the
Renila luciferase to obtain an arbitrary unit of transcription. The fold of activation
was calculated by dividing the transcription unit of a given sample by the
transcription unit of the sample without myc-Brn3a or myc-Klf7.
In situ hybridization
The digoxigenin (DIG) nonisotopic in situ hybridization using 14-μm
cryostat sections was carried out as described (Lei et al., 2005). The antisense
RNA probes include Brn3a and Klf7.
Immunohistochemistry
14-μm cryostat sections were processed for immunohistochemistry as
previously described using either fluorophore-conjugated secondary antibodies
or biotinylated secondary antibodies (Lei et al., 2005). Primary antibodies used in
this study were: NeuN (mouse, Chemicon, 1:500), TrkA (rabbit, L.F. Reichardt,
UCSF, 1:5000), TrkB (chick, L.F. Reichardt, UCSF, 1:500), TrkC (goat, L.F.
Reichardt, UCSF, 1:500), Ret (rabbit, IBL, 1:50), NF150 (rabbit, Chemicon,
1:500), Neurogenin1 (rabbit, Jane Johnson, 1:5000), CGRP (rabbit, Sigma,
1:1000), parvalbumin (rabbit, Swant, 1;1000), phosphorylated histone H3
(rabbit, Upstate, 1:100), and activated caspase 3 (rabbit, Cell Signaling, 1:100).
DAPI was added at 1 μg/ml together with the secondary antibodies for detecting
the nuclei. Secondary antibodies were from the Jackson ImmunoResearch
Laboratories. Images were collected on an Olympus BX50 fluorescence
microscope using a digital camera and analyzed using the MetaMorph software
(Universal Imaging Corporation). When biotin-conjugated secondary antibodies
were used, signals were detected using the ABC kit and DAB reagent (Signet).
Cell counts
Phosphorylated histone H3(+) cells and activated caspase 3(+) cells were
counted under an Olympus BX50 fluorescencemicroscope. The numbers of total
neurons, TrkA(+) neurons, and Ret(+) neurons in P0 trigeminal ganglia were
counted as previously described using serial sections (Lei et al., 2005).
Whole-mount X-gal staining
X-gal staining was done as described (Ma et al., 2003). Trigeminal ganglia
from P0 mice were dissected out, fixed in 4% paraformaldehyde (PFA) for 1 h,
washed in 1× PBS twice for 10 min, and incubated overnight at 37°C in 400 μl
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potassium ferrocyanide, 2 mMMgCl2, 1 mg/ml X-gal, and 0.02%Nonidet P-40.
Samples were washed in 1× PBS twice for 10 min and postfixed in 4% PFA
overnight. Images were collected on a dissecting microscope (Leica) using a
digital camera.Results
Brn3a and Klf7 are independently regulated
It was previously known that Brn3a and Klf7 are expressed
in a majority of sensory neurons in the trigeminal ganglion
(Artinger et al., 1998; Fedtsova and Turner, 1995; Lei et al.,
2001; Xiang et al., 1995). This is confirmed by in situ
hybridization using Brn3a and Klf7 anti-sense RNA probes
(Fig. 1). To examine whether either of these transcription factors
is under regulation by the other, we examined Brn3a expression
in Klf7 null embryos and vice versa. At E12.5 and at P0, Brn3a
expression is normal in Klf7 null trigeminal ganglion and Klf7Fig. 1. Brn3a and Klf7 synergistically activate the TrkA minimal enhancer in vitro. (A
E12.5 trigeminal ganglia of indicated genotypes. (E–L) In situ hybridization of P0 tr
areas in panels E–H. Scale bars: A–H, 100 μm; I–L, 50 μm. (M) Dual-luciferase re
amount. The total amount of expression plasmids was adjusted using the cloning veexpression is normal in Brn3a null trigeminal ganglion (Figs.
1A–L). Thus, Brn3a and Klf7 are expressed independently of
one another in sensory neurons.
Brn3a and Klf7 synergistically activate the TrkA minimal
enhancer in vitro
In vivo, the absence of Klf7 results in a reduction in
endogenous TrkA expression and the absence of Brn3a also has
a partial effect on TrkA expression (Huang et al., 1999; Lei et al.,
2005; Ma et al., 2003). In vitro, Klf7 can activate the TrkA
minimal enhancer in a sequence-dependent manner (Lei et al.,
2005). To examine whether Klf7 and Brn3a can cooperate in
enhancer activation, PC12 cells were cotransfected with a TrkA
enhancer dependent luciferase construct and expression plas-
mids for Klf7 and/or Brn3a. As shown in Fig. 1M, Brn3a alone
does not activate the TrkA minimal enhancer in PC12 cells.
However, when added together, Brn3a and Klf7 can synergis-
tically activate the TrkA minimal enhancer. Thus in a tissue–L) Brn3a and Klf7 are independently regulated. (A–D) In situ hybridization of
igeminal ganglia of indicated genotypes. Panels I–L were taken from the boxed
porter assay. Myc-tagged Brn3a and Klf7 plasmids were added at the indicated
ctor CS2+MT. The fold of transcriptional activation was indicated.
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minimal enhancer.
Expression of Trk receptors during development
To determine the physiological relevance of the preceding
studies, we turned to analysis of combined mutants of Brn3a
and Klf7. We examined Trk receptor expression throughout
embryonic development in the context of these two mutations.
E11.5
The birth of sensory neurons in the trigeminal ganglion
occurs in two waves: Neurogenin 2 (Ngn2) marks cells that are
born early and destined to become TrkC(+) and TrkB(+)
neurons, while Neurogenin 1 (Ngn1) marks cells that are born
late and destined to become TrkA(+) neurons (Ma et al., 1999).
Nissl staining indicates that trigeminal ganglia appear normal in
all genotypes (Figs. 2A1–A4). As shown in Figs. 2B1–B4, the
expression of Ngn1 is normal, indicating that the precursor cells
destined to become TrkA(+) neurons are present. More
importantly, the initiation of TrkA expression at E11.5 is
normal in all genotypes including the Brn3a−/−;Klf7−/− double
knockouts (Figs. 2C1–C4). This suggests that both Brn3a and
Klf7 are dispensable for the initiation of TrkA expression in
vivo. While TrkB expression is normal in all genotypes, TrkC is
not expressed in Brn3a−/− or Brn3a−/−;Klf7−/− mutants (Figs.
2D1–F4). This is consistent with previous observations (Huang
et al., 1999). The expression of the mitosis marker phosphor-
ylated histone H3 (PH-3) is similar in all mutants, suggesting
normal cell proliferation (Figs. 2G1–G4). Moreover, the
expression of activated caspase 3 (AC-3) is undetectable in all
genotypes, suggesting no significant difference in apoptosis
(Figs. 2H1–H4).
E12.5
At E12.5, Nissl staining indicates that the trigeminal ganglia
are smaller in Brn3a−/−, Klf7−/−, and double knockout
mutants, compared with Brn3a+/−;Klf7+/− controls (Figs.
3A1–A4). Anti-NF150 (neurofilament 150) staining indicates
that the early differentiation of sensory neurons occurs normally
in all mutants (Figs. 3B1–B4). The expression of PH-3 is
similar in all mutants (Figs. 3C1–C4). We counted the number
of PH-3(+) cells per section and obtained the following values:
49±3 for Brn3a+/−;Klf7+/−, 51±4 for Brn3a−/−, 48±3 for
Klf7−/−, and 46±5 for Brn3a−/−;Klf7−/− (P>0.05, N=10
sections for each genotype), suggesting normal cell prolifera-
tion in all mutants. The expression of TrkA appears normal in
Brn3a−/− trigeminal ganglia and is only slightly reduced in
Klf7−/− trigeminal ganglia (Figs. 3D1–D3; Huang et al., 1999).
However, the expression of TrkA is almost completely
abolished in Brn3a−/−;Klf7−/− trigeminal ganglia (Fig. 3D4).
This suggests that Brn3a and Klf7 are partially redundant in
regulating the early expression of TrkA and the loss of both
genes leads to a severe reduction in TrkA expression in vivo.
Consistent with previous results, the expression of TrkB is
slightly increased in Brn3a−/− and Brn3a−/−;Klf7−/− trigem-
inal ganglia, while its expression is normal in Klf7−/−trigeminal ganglia (Figs. 3E1–E4) (Huang et al., 1999; Lei et
al., 2005). TrkC is not expressed in either Brn3a−/− or Brn3a−/−;
Klf7−/− trigeminal ganglia although its expression is normal in
Klf7−/− trigeminal ganglia, confirming that Brn3a but notKlf7 is
required for TrkC expression (Figs. 3F1–F4) (Huang et al., 1999;
Lei et al., 2005).
E15.5
Nissl staining indicates that there is an increase in apoptosis
in Brn3a−/−, Klf7−/−, and Brn3a−/−;Klf7−/− trigeminal
ganglia, as evidenced by the appearance of pyknotic nuclei
(Figs. 4B1–B4, arrowheads). This is further confirmed by AC-3
immunohistochemistry, which specifically labels apoptotic cells
(Figs. 4H1–H4). We counted the number of apoptotic cells per
section and obtained the following values: 10±2 for Brn3a+/−;
Klf7+/−, 29±3 for Brn3a−/− (P<0.001), 26±3 for Klf7−/−
(P<0.001), and 48±5 for Brn3a−/−;Klf7−/− (P<0.001),
N=10 sections for each genotype. The expression of TrkA is
significantly reduced in Brn3a−/− and Klf7−/− trigeminal
ganglia, and is completely abolished in the double knockouts
(Figs. 4C1–C4). This indicates that Brn3a and Klf7 are required
for the maintenance of TrkA expression. The expression of
TrkB is normal in all genotypes while TrkC is not expressed in
Brn3a−/− or Brn3a−/−;Klf7−/− trigeminal ganglia (Figs. 4D1–
E4). The reduced expression of TrkA and TrkC likely caused
the increased cell death in the mutants (Figs. 4H1–H4).
P0
By P0, sensory neurons in trigeminal ganglia can be readily
distinguished by their relatively large cell bodies on H&E-
stained sections (Figs. 5A1–A4) (Lei et al., 2005). There is a
severe reduction of neurons in Brn3a−/− trigeminal ganglia
and a partial reduction of small neurons in Klf7−/− trigeminal
ganglia and most neurons disappeared in Brn3a−/−;Klf7−/−
trigeminal ganglia. This is confirmed by anti-NeuN immuno-
histochemistry, which specifically label neuronal nuclei (Figs.
5B1–B4). We next examined the expression of Trk receptors.
Consistent with previous results, TrkA expression is only
partially reduced in Brn3a−/− trigeminal ganglia (Figs. 5C1–
C2) (Ma et al., 2003). TrkA expression is also partially
reduced in Klf7−/− trigeminal ganglia (Fig. 5C3) and it is
completely abolished in Brn3a−/−;Klf7−/− trigeminal ganglia
(Fig. 5C4). By P0, TrkB is no longer detected in Brn3a−/− or
Brn3a−/−;Klf7−/− trigeminal ganglia, although its expression
is normal in Klf7−/− trigeminal ganglia (Figs. 5D1–D4),
indicating a progressive loss of TrkB expression in Brn3a−/−
and Brn3a−/−;Klf7−/− trigeminal ganglia. TrkC is not
expressed in Brn3a−/− or double mutant trigeminal ganglia
(Figs. 5E1–E4). Consistent with previous results, the expres-
sion of the GDNF receptor Ret is normal in Brn3a−/− and
Klf7−/− trigeminal ganglia (Figs. 5H1–H3) (Huang et al.,
1999; Lei et al., 2005). Importantly, Ret expression is also
normal in Brn3a−/−;Klf7−/− trigeminal ganglia, indicating that
both Brn3a and Klf7 are dispensable for its expression (Fig. 5H4).
Wenext counted the number of total neurons, TrkA(+) neurons, and
Ret(+) neurons in the different genotypes using serial sections
(Table 1).We found thatwhile there is a significant reductionof total
Fig. 2. TrkA expression is initiated in Brn3a−/−;Klf7−/− trigeminal ganglia at E11.5. (A1–A4) Nissl staining to indicate the formation of trigeminal ganglia. (B1–B4)
Neurogenin1 immunohistochemistry to label precursor cells of TrkA(+) neurons. (C1–C4) TrkA immunohistochemistry. (D1–D4) TrkB immunohistochemistry. (E1–
E4) TrkC immunohistochemistry. (F1–F4) DAPI staining to label the nuclei. (G1–G4) Phosphorylated histone H3 immunohistochemistry to label the mitotic cells.
(H1–H4) Activated caspase 3 immunohistochemistry to label apoptotic cells. Scale bars: A1–A4, 100 μm; B1–F4, 100 μm; G1–G4, 200 μm; H1–H4, 100 μm.
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Fig. 3. TrkA expression is severely down-regulated in Brn3a−/−;Klf7−/− trigeminal ganglia at E12.5. (A1–A4) Nissl staining to indicate the formation of trigeminal
ganglia. (B1–B4) NF150 immunohistochemistry to label early differentiated neurons. (C1–C4) Phosphorylated histone H3 immunohistochemistry to label mitotic
cells. (D1–D4) TrkA immunohistochemistry. (E1–E4) TrkB immunohistochemistry. (F1–F4) TrkC immunohistochemistry. (G1–G4) Triple labeling of TrkA, TrkB,
and TrkC. (H1–H4) DAPI staining to label the nuclei. Scale bars: A1–C4, 200 μm; D1–H4, 100 μm.
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number of Ret(+) neurons remain unchanged. Taken together, these
data are consistent with our in vitro findings (Fig. 1). They furtherconfirm the partial requirement for Brn3a and Klf7 for endogenous
TrkA gene expression and indicate a cooperative effect of these
transcription factors in vivo.
Fig. 4. TrkA expression is completely abolished in Brn3a−/−;Klf7−/− trigeminal ganglia at E15.5. (A1–A4) Nissl staining. (B1–B4) High magnifications of boxed
areas in panels A1–A4. (C1–C4) TrkA immunohistochemistry. (D1–D4) TrkB immunohistochemistry. (E1–E4) TrkC immunohistochemistry. (F1–F4) Triple labeling
of TrkA, TrkB, and TrkC. (G1–G4) DAPI staining to label the nuclei. (H1–H4) Immunohistochemistry using the antibody against activated caspase 3 (AC-3) to label
the apoptotic cells. Scale bars: A1–A4, 50 μm; C1–G4, 50 μm; H1–H4, 100 μm.
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Fig. 5. All prospective Trk(+) neurons are lost in Brn3a−/−;Klf7−/− trigeminal ganglia at P0. (A1–A4) H&E staining. (B1–B4) NeuN immunohistochemistry. (C1–
C4) TrkA immunohistochemistry. (D1–D4) TrkB immunohistochemistry. (E1–E4) TrkC immunohistochemistry. (F1–F4) Triple labeling of TrkA, TrkB, and TrkC.
(G1–G4) DAPI staining to label the nuclei. (H1–H4) Ret immunohistochemistry. Scale bars: A1–B4, 50 μm; C1–H4, 100 μm.
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neurons, TrkA and TrkC are required for the expression of
CGRP and parvalbumin respectively (Patel et al., 2000,
2003). As shown in Fig. 6, while the expression of
parvalbumin is normal in Klf7−/− and Brn3a+/−;Klf7+/−trigeminal ganglia, it is completely abolished in Brn3a−/−
mutants and the double knockouts. In addition, the expression
of CGRP is severely reduced in Brn3a−/− and Klf7−/−
trigeminal ganglia, while it is completely abolished in the
double knockouts. These results are consistent with the
Table 1
Neuron counts in P0 trigeminal ganglia
B+/−K+/− B−/− K−/− B−/−K−/−
Total 45768±2490 14128±928* 31926±1422* 4488±262*
TrkA(+) 32038±1812 9611±412* 16282±986* 0*
Ret(+) 4577±256 4244±196 4180±268 4592±164
N=4 trigeminal ganglia for each genotype. *p<0.05, t test. B, Brn3a; K, Klf7.
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genotypes.
The TrkA minimal enhancer is inactive in Brn3a−/−;Klf7−/−
trigeminal ganglia
We previously generated a stable transgenic line expressing
the β-galactosidase reporter gene under the control of the TrkA
minimal enhancer, which specifically drives the expression ofβ-
galactosidase in TrkA(+) sensory neurons (Ma et al., 2000,
2003). To independently confirm the immunohistochemistry
data (Fig. 5), we genetically crossed both Brn3a and Klf7 mutant
alleles into the TrkA enhancer-LacZ reporter mice background
and examined the TrkA enhancer activity by whole amount X-
gal staining of P0 trigeminal ganglia (Fig. 7). While LacZ
expression is normal in Brn3a+/−, Klf7+/−, and Brn3a+/−;
Klf7+/−, it is partially reduced in Brn3a−/− and Klf7−/−
trigeminal ganglia (Figs. 7A–F). Most importantly, LacZ
expression is completely abolished in Brn3a−/−;Klf7−/−
trigeminal ganglia (Fig. 7I). Interestingly, the reduction in
LacZ expression is more severe in compound knockout/
heterozygous mutants than in each respective knockoutFig. 6. Expression of CGRP and parvalbumin at P0. (A–D) Expression of parvalbum
bars: A–D, 50 μm; E–L, 100 μm.mutant alone (Figs. 7E–H). These results suggest a dosage
requirement and a genetic interaction for Brn3a and Klf7 in
regulating TrkA expression in vivo.
Discussion
Combinatorial control of gene regulation
Cell fate specification and differentiation during embryonic
development require the establishment of unique regulatory
programs that dictate cell-type-specific patterns of gene
expression. Transcriptional regulation in the mammalian
nervous system involves a complex array of gene expression
patterns that must be controlled by a genome of limited size.
The “combinatorial” theory of gene regulation proposes that
most genes are regulated by multiple transcription factors, each
of which participates in controlling the expression of a variety
of genes with different expression patterns (Britten and
Davidson, 1969; Ernst and Smale, 1995; Georgiev, 1969;
Gierer, 1974). The expression of a given gene therefore depends
on the interaction of a specific combination of transcription
factors with the cis regulatory elements of this gene.
The TrkA minimal enhancer contains multiple highly
conserved cis regulatory elements (Ma et al., 2000). Many of
these conserved cis elements are important for the enhancer
function. This suggests that multiple transcription factors
participate in the regulation of TrkA gene expression. In two
independent studies, we previously demonstrated that Brn3a
and Klf7 each is required for appropriate TrkA expression in
sensory neurons (Lei et al., 2005; Ma et al., 2003). The current
study demonstrates that expression of Brn3a and Klf7 isin. (E–H) Expression of CGRP. (I–L) DAPI staining to label the nuclei. Scale
Fig. 7. The TrkA minimal enhancer is inactive in Brn3a−/−;Klf7−/− trigeminal ganglia at P0. Whole-mount X-gal staining of P0 trigeminal ganglia of indicated
genotypes is shown. The number of samples examined for each genotype is labeled. B, Brn3a; K, Klf7.
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requirement for both factors in regulating TrkA expression in
vivo is additive. The loss of both genes gave a more severe
phenotype than the loss of each gene individually.
Although Brn3a and Klf7 together can activate the TrkA
minimal enhancer in PC12 cells, they cannot be sufficient to
activate the endogenous TrkA gene in vivo. For example, Brn3a
and Klf7 are also coexpressed in TrkB(+) and TrkC(+) sensory
neurons where TrkA is not expressed. This suggests that Brn3a
and Klf7 work within a cellular context to regulate TrkA
expression. Thus additional yet unidentified positive regulators
participate in activating TrkA expression in presumptive TrkA
(+) neurons, and/or negative regulators are present in TrkB(+)
and TrkC(+) cells to repress TrkA expression in these neurons
(Ma et al., 2000). The interaction ofmultiple transcription factors
ensures a tightly regulated pattern of TrkA expression in vivo.
Initiation and maintenance of TrkA transcription
TrkA protein can be detected in mouse trigeminal ganglia at
E11.5. Its expression peaks at E13.5 and remains stable in
adulthood. This study demonstrates that the initiation of TrkA
expression at E11.5 is independent of both Brn3a and Klf7.
Thus, other transcription factors must participate in the early
phase of TrkA expression. However, 1 day later, TrkA
expression is severely reduced in the double knockouts. By
E15.5, no TrkA can be detected in the double knockouts. Thus,
both Brn3a and Klf7 are required for the late phase and the
maintenance of TrkA expression. As suggested by the enhancer
analysis, additional transcription factors must be identified so
that we can fully understand the molecular mechanism that
regulates TrkA expression in vivo (Ma et al., 2000).
Brn3a and Klf7 influence TrkA mediated survival
In the absence of both Brn3a and Klf7, the precursor cells
that are destined to become TrkA(+) neurons are present atE11.5 (Fig. 2). Moreover, the trigeminal ganglia appear
normal in the mutants at this early developmental stage.
Therefore, both Brn3a and Klf7 are dispensable for the
patterning of trigeminal ganglia and the cell fate specifica-
tion. Furthermore, they are also dispensable for the
proliferation and early differentiation of these cells (Fig. 3).
However, the ablation of both Brn3a and Klf7 leads to the
complete loss of Trk receptor expression and ultimately the
loss of neurons (Table 1). Thus, both Brn3a and Klf7 are
important survival factors for the primary sensory neurons by
regulating the expression of Trk receptors. By crossing the
Brn3a mutant allele and the Klf7 mutant allele into the Bax
null background to maintain neurons alive, we previously
demonstrated that the reduction of TrkA expression is a direct
effect of Brn3a or Klf7 gene ablation, respectively, rather
than a secondary effect of cell death (Lei et al., 2005; Ma et
al., 2003). Therefore, we propose that the loss of TrkA
expression in the double knockouts is also a direct effect of
Brn3a and Klf7 gene ablation, rather than a secondary effect
of cell death.
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